Internet Pioneer In...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$2.74 0.04 | 1.29%
06/04/12 - 03:44 PM ET
Insider Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Net Insider Transaction | 0 | 0 | 12,664 | 12,664 | 12,664 | 0 | 0 |
| Shares Bought | 0 | 0 | 52,500 | 52,500 | 52,500 | 0 | 3,000 |
| Shares Sold | 0 | 0 | 39,836 | 39,836 | 39,836 | 0 | 3,000 |
Institutional Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Total Shares Held | 57.84M | 61.13M | 62.74M | 62.38M | 50.46M | 50.46M | 50.46M |
| Shares Bought | 4.71M | 15.39M | 15.63M | 15.62M | 12.29M | 12.29M | 12.29M |
| Shares Sold | 7.39M | 2.71M | 3.24M | 2.53M | 4.39M | 4.39M | 4.39M |
Portfolios with CADX
- Portfolio NameUser Type
- Contributor8 Stocks Below $10 To Avoid
- Contributor10 Most Shorted Stocks in B...
- ContributorRelative Strength Stocks 09...
- Usergrainey Portfolio 1
- Useryourguess Portfolio 1
- Userlives288
- UserCarl Nicola Portfolio 1
- Userron stewart
Latest CADX Headlines from TheStreet
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
- Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge 10.31.11 | 11:10 am
- 5 Stocks Showing Relative Strength in a Weak Market 09.22.11 | 02:09 pm
- Biotech Stock Mailbag: Cadence Pharma 03.11.11 | 07:03 am
- Biotech Sector Weekly Rewind 11.06.10 | 09:11 am
- Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript 11.05.10 | 02:11 pm
- Cadence: When A Drug Approval Sinks Stock 11.03.10 | 10:11 am
- FDA Ends October With Drug Approvals, Rejection 11.01.10 | 07:11 am
- Biotech Stock Mailbag: Exact Sciences 10.15.10 | 07:10 am
- 21 Drugs Facing FDA Approval Decisions 08.31.10 | 08:08 am
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
